NGeneBio Co., Ltd.
KKRX:354200700.00
KRW
-21.00
(-2.91%)
ISIN
KR7354200008
Return %
Stock
S&P 500
1Y
-82.55
14.39
3Y
-93.98
81.42
5Y
-98.10
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Min-Sik Kim
- Full Time Employees
- 56
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Seoul South Korea
- IPO Date
- Dec 10, 2020
- Website
- ngenebio.com
- Similar Companies
- Business
- NGeneBio Co., Ltd. is a South Korea-based biotechnology and precision diagnostics company specializing in next-generation sequencing (NGS)-based molecular diagnostic assays, bioinformatics analysis software, and precision medicine platforms. Founded in 2015 and headquartered in Seoul, South Korea, the company develops, manufactures, and commercializes integrated clinical diagnostic solutions that combine reagent kits with automated interpretation software to serve hospitals, clinical laboratories, diagnostic centers, and research institutions across the Asia-Pacific region, Europe, and the Middle East. The company's core operations are structured into specialized diagnostic and software product lines: Oncology and Genetic Diagnostic Panels, which include BRCAaccuTest and BRCAaccuTest PLUS for hereditary breast and ovarian cancer risk assessment; SOLIDaccuTest for solid tumor somatic mutation profiling; HEMEaccuTest for hematological malignancies and blood cancer variant detection; MRDaccuPanel AML FLT3 for minimal residual disease monitoring; ONCOaccuPanel for comprehensive cancer genomic profiling; and HLAaccuTest for human leukocyte antigen typing in organ and hematopoietic stem cell transplantation; Clinical Bioinformatics Software and Digital Health Systems, comprising NGeneAnalySys, an automated clinical genomic analysis and variant interpretation platform; EasyHLAanalyzer for HLA genotyping data analysis; and Next-generation Genomic Laboratory Information System (NGLIS), an integrated laboratory software platform connecting hospital Electronic Medical Record systems with NGS workflow pipelines; and Companion Diagnostics and Clinical Testing Services, offering customized biomarker discovery, companion diagnostics co-development for pharmaceutical partners, infectious disease testing assays, and clinical research sequencing services. In recent corporate developments, NGeneBio has expanded its clinical diagnostic portfolio, international commercial reach, and corporate structure. The company executed an international technology transfer agreement with Euro Alliance to establish local manufacturing and joint venture operations across the United Arab Emirates and India; partnered with LG AI Research to advance artificial intelligence-driven EGFR mutation detection models; formed a clinical research collaboration with Yonsei Medical Center for NGS-based immunotherapy response prediction; partnered with MGI Tech to integrate NGeneBio diagnostic panels on high-throughput sequencing systems; acquired healthcare and pharmaceutical distributor Nuripharm, subsequently renamed NGene Pharma, and completed its internal merger to build an integrated healthcare distribution framework; completed the divestiture of its proteomics subsidiary NGeneBioAI to Yatiri Bio; secured domestic medical device manufacturing approvals for its MRDaccuPanel AML FLT3 blood cancer monitoring assay; and secured exclusive technology transfer rights for the NGLIS genomic laboratory data system developed with Asan Medical Center to accelerate digital workflow integration across tertiary hospital networks.